Nov. 25, 2013
/PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr.
Mark A. Sirgo
, President and Chief Executive Officer of BDSI, will present at the 25
Annual Piper Jaffray Healthcare Conference. The presentation is scheduled for
Wednesday, December 4, 2013
1:00 p.m. Eastern Time
at The New York Palace.
BDSI submitted a New Drug Application (NDA) for BUNAVAIL for the treatment of opioid dependence, and based on timelines established by the Prescription Drug User Fee Act (PDUFA), the review of the BUNAVAIL NDA is expected to be completed by
June 7, 2014
. Dr. Sirgo will be providing an update on BUNAVAIL commercial options and the anticipated market opportunity.
Additionally, Dr. Sirgo will provide an update on the progress made by BDSI and its commercial partner, Endo Health Solutions, with the ongoing Phase 3 clinical program for BEMA Buprenorphine for the treatment of chronic pain along with updated plans for the initiation of the pivotal clinical trial program for Clonidine Topical Gel for the treatment of painful diabetic neuropathy.
The presentation will be webcast live and can be accessed at
. For those who are not available to listen to the live broadcast, a replay of the webcast will be available on the BDSI website.
About BioDelivery Sciences International
BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction.